Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications

SETTING:

Rifampicin (RMP) drives treatment response in drug-susceptible tuberculosis. Low RMP concentrations increase the risk of poor outcomes, and drug quality needs to be excluded as a contributor to low RMP exposure.

OBJECTIVES AND DESIGN:

We performed an open-label, three-way cross-over study of three licensed RMP-containing formulations widely used in South Africa to evaluate the bioavailability of RMP in a two-drug fixed-dose combination tablet (2FDC) and a four-drug FDC (4FDC) against a single-drug reference. RMP dosed at 600 mg was administered 2 weeks apart in random sequence. Plasma RMP concentrations were measured pre-dose and 1, 2, 3, 4, 6, 8 and 12 h post-dose. The area under the concentration-time curve (AUC_0–12) of the FDCs was compared to the single drug reference. Simulations were used to predict the impact of our findings.

RESULTS:

Twenty healthy volunteers (median age 22.8 years, body mass index 24.2 kg/m²) completed the study. The AUC_0–12 of the 4FDC/reference (geometric mean ratio [GMR] 78%, 90%CI 69–89) indicated an average 20% reduction in RMP bioavailability in the 4FDC. The 2FDC/reference (GMR 104%, 90%CI 97–111) was bioequivalent. Simulations suggested dose adjustments to compensate for the poor bioavailability of RMP with the 4FDC, and revised weight-band doses to prevent systematic underdosing of low-weight patients.

CONCLUSION:

Post-marketing surveillance of in vivo bioavailability of RMP and improved weight band-based dosing are recommended.

Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes

SETTING

To assess the revised World Health Organization-recommended dose of 10-20 mg/kg rifampicin (RMP), we studied the steady state pharmacokinetics of RMP in South African children who received standard treatment for drug-susceptible tuberculosis (TB).

OBJECTIVE

To determine the formulation effect on the pharmacokinetics of RMP.

DESIGN

RMP plasma concentrations were characterised in 146 children (median age 1.4 years, range 0.2-10.2). The morning dose on the day of the pharmacokinetic evaluation was administered as one of two RMP single-drug oral suspensions.

RESULTS

While one formulation achieved 2 h concentrations in the range of those observed in adults (median 6.54 mg/l, interquartile range [IQR] 4.47-8.84), the other attained a median bioavailability of only 25% of this, with a median 2 h concentration of 1.59 mg/l (IQR 0.89-2.38).

CONCLUSION

RMP is a key drug for the treatment of TB. It is critical that the quality of RMP suspensions used to treat childhood TB is ensured.

Grain sizes, surface areas, and porosities of vapor-deposited H2O ices used to simulate planetary icy surfaces

Mean grain sizes and specific surface areas (SSAs) of ice substrates formed by vapor deposition at low temperatures are of importance in simulating external surfaces of icy satellites in the solar system. Environmental scanning electron microscopy (ESEM) was used to obtain granule sizes and to observe the phase of ice granules prepared on borosilicate, silicon, and metallic plates. Ices prepared at a temperature lower than 140 K appear to be amorphous, and their granule sizes are typically submicrometer. At slightly warmer temperatures, near 180-200 K, ice films are composed of either hexagonal or cubic granules with sizes up to a few micrometers. When briefly annealed to even warmer temperatures, ice granule sizes approach approximately 10 microm. SSAs of ice substrates were determined from BET (Brunauer, Emmett, and Teller) analysis of gas adsorption isotherms in the temperature range from 83.5 to 261 K. SSAs decrease drastically from 102 m2/g at 83.5 K to 0.87 m2/g at 150 K and further decrease slowly to 0.22 m2/g at 261 K, suggesting that the transition from amorphous to crystalline forms occurs at approximately 150 K. The overall decrease in SSAs is primarily due to metamorphism and sintering. These results are comparable to recent field and laboratory measurements. Possible implications for theoretical models of icy satellites of outer planets using remote sensing techniques are also discussed.

Prometheus: Io's wandering plume

Unlike any volcanic behavior ever observed on Earth, the plume from Prometheus on Io has wandered 75 to 95 kilometers west over the last 20 years since it was first discovered by Voyager and more recently observed by Galileo. Despite the source motion, the geometric and optical properties of the plume have remained constant. We propose that this can be explained by vaporization of a sulfur dioxide and/or sulfur "snowfield" over which a lava flow is moving. Eruption of a boundary-layer slurry through a rootless conduit with sonic conditions at the intake of the melted snow can account for the constancy of plume properties.

Near-infrared spectroscopy and spectral mapping of Jupiter and the Galilean satellites: results from Galileo's initial orbit

The Near Infrared Mapping Spectrometer performed spectral studies of Jupiter and the Galilean satellites during the June 1996 perijove pass of the Galileo spacecraft. Spectra for a 5-micrometer hot spot on Jupiter are consistent with the absence of a significant water cloud above 8 bars and with a depletion of water compared to that predicted for solar composition, corroborating results from the Galileo probe. Great Red Spot (GRS) spectral images show that parts of this feature extend upward to 240 millibars, although considerable altitude-dependent structure is found within it. A ring of dense clouds surrounds the GRS and is lower than it by 3 to 7 kilometers. Spectra of Callisto and Ganymede reveal a feature at 4. 25 micrometers, attributed to the presence of hydrated minerals or possibly carbon dioxide on their surfaces. Spectra of Europa's high latitudes imply that fine-grained water frost overlies larger grains. Several active volcanic regions were found on Io, with temperatures of 420 to 620 kelvin and projected areas of 5 to 70 square kilometers.